Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Pulse Therapy for Kawasaki Disease Aneurysms
NCT04509219Phase 1Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylprednisolone in Kawasaki disease (KD), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and physical effects at 24 weeks. Status: unknown.
02
Drugs
methylprednisolone
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT04509219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509219.